KindlyMD (NASDAQ:NAKA) Stock Rating Upgraded by Wall Street Zen

KindlyMD (NASDAQ:NAKA – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Other research analysts have also recently issued research reports about the stock. B. Riley Financial upped their target price on shares of KindlyMD from $11.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, September 22nd. TD Cowen increased their target price on shares of KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KindlyMD in a research note on Wednesday, November 4th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Read Our Latest Research Report on NAKA

KindlyMD Stock Performance

Shares of NAKA opened at $5.00 on Friday. The stock has a 50 day moving average price of $7.87 and a 200 day moving average price of $7.52. The company has a quick ratio of 0.23, a current ratio of 0.23 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $91.75 million, a price-to-earnings ratio of -0.33 and a beta of 16.03. KindlyMD has a 52-week low of $3.33 and a 52-week high of $25.22.

KindlyMD (NASDAQ:NAKA – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported $4.07 EPS for the quarter, beating the consensus estimate of ($0.49) by $4.56. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 73.53%. The company had revenue of ($1.93) million for the quarter. Research analysts predict that KindlyMD will post -12.94 EPS for the current fiscal year.

Insider Buying and Selling at KindlyMD

In other news, CEO David F. Bailey bought 4,852 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was purchased at an average cost of $6.27 per share, with a total value of $30,422.04. Following the transaction, the chief executive officer directly owned 3,185,246 shares in the company, valued at $19,971,492.42. This trade represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders bought 41,904 shares of company stock valued at $235,231. 24.08% of the stock is currently owned by insiders.

KindlyMD Company Profile

(Get Free Report)

KindlyMD is a Utah-based healthcare company that provides outpatient medical services, with a focus on integrated care. Its offerings include primary care, behavioral health and treatment for substance use disorders, along with care coordination intended to connect patients with appropriate services. The company serves patients through clinics in Utah and has emphasized care for people with complex or ongoing health needs. KindlyMD combined with Nakamoto Holdings in 2025; the resulting company trades on Nasdaq under the symbol NAKA.

See Also

Receive News & Ratings for KindlyMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KindlyMD and related companies with MarketBeat.com's FREE daily email newsletter.